Fierce Healthcare December 7, 2022
By Alison Lum, Edward Fotsch

This is the third in a series of articles that looks at the current state of drug cost transparency for prescribers, pharmacists, and patients. The first two articles can be found here and here.

The first and second articles in this series focused on the promise and challenges with real-time prescription benefit (RTPB), including the need to move beyond transparency solely when ordering new prescriptions through the electronic health record.

This third article expands the focus of drug cost transparency to include all of a patient’s current medications and all relevant points of patient care and communications. While cost transparency to prescribers in EHRs is essential, there are many other relevant and important stakeholders in the care...

Today's Sponsors


Today's Sponsor


Topics: Pharma, Pharma / Biotech
J&J to shut down massive Bay Area R&D facility less than 18 months after opening it
Pharmacies Can Leverage Clinical Opportunities to Diversify, Increase Revenue
FDA Updates for the Week of Feb 19: Cancer Approval Revoked
Pharmacy Technicians, Rural Areas Benefit From Expansion of Telepharmacy
What do CEOs owe the world?

Share This Article